Four Undervalued Chinese Pharmas

China OTC Player submits:By Platinum Tiger

China OTC Player submits:Whoever said that life is full of mysteries could have been pondering the story of Jiangbo Pharmaceuticals (JGBO). I’ve been scratching my head over this company for more than a year now, mystified as to why investors aren’t valuing it at a price at least 4-5 times its current valuation. This may well be the best bargain on all of the U.S. stock exchanges.

China OTC Player submits:As you can see from visiting my site, it is no longer called "China OTC Player" but "China OTC and Opportunity Player". This is to allow me to focus on some of the lesser known but emerging stocks on the major exchanges. I believe some of these counters present really interesting investment opportunities, and I will be sharing my thoughts on them in the near future.

China OTC Player submits:By Platinum TigerPowered by a 10 percent rise last week in the pharmaceuticals sector, the 35 stock China OTC Player small cap index surged to its fifth weekly gain in the past six weeks, closing just below its record high of January 15th.Complete Story »

China OTC Player submits:Jiangbo Pharmaceuticals, Inc. (JGBO.OB) is a small cap pharmaceutical and health supplement manufacturer and distributor in the PRC.With an estimated $155-$160 million cash in the bank, a solid EPS growth rate, $40 million in fiscal 2010 free cash flow (according to the CFO), low debt, and a market cap of just $160 million, JGBO appears to be significantly undervalued.

China OTC Player submits:By Platinum TigerA 10 percent plunge in real estate stocks cooled off the Rising China Stocks (RCS) index for a second consecutive week, wiping out nearly a third of the gains the small cap index had made this year and putting it well off the pace of the red hot Russell 2000 small cap index, which is now up by nearly 20 percent this year.

Douglas Estadt submits: Tianyin Pharmaceutical Co. (TPI) is a Chinese company offering traditional Chinese medicine as well as more modern and westernized types of medication. This gives the company an advantage, as it increases their potential customer base - as does their mix of prescription/over the counter offerings. TPI is positioned to grow, with 39 drugs in their portfolio and 17 more in the pipeline.

Double Dividend Stocks submits: We’re continuing our quest for international dividend stocks this week with 3 Chinese dividend paying stocks that all have low PEG/ high EPS growth forecasts, low debt, strong management metrics, and options trading available. All 3 of these stocks trade in the US.This group includes an oil & gas firm, an insurance company, and a drug manufacturer.